The esketamine MDD efficacy/safety study will report data consistent with its label, reinforcing non-classic mechanisms as the near-term clinical winner.

Esketamine — sold as Spravato, a nasal spray already approved for hard-to-treat depression — is expected to produce new research data by mid-November 2026 that confirms it works safely as the label already says. This matters because it would reinforce that ketamine-related drugs, which don't have the blinding problems that psychedelics do, are currently the most realistic near-term option for people with severe depression.

Esketamine's mechanism and blinding are established; it outpaces psilocybin on the regulatory path this fall.